Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
148
Active, not recruiting, industry sponsors, Hematology and blood cancers, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting155
- Completed859
148 trials
Showing 1 to 25, recently updated first.
- A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With AnemiaPivotal-lookingActive, not recruiting
Kind Pharmaceuticals LLCIndustry
NCT07494409 · 300 participants (planned) · Start Oct 31, 2025 · Primary completion Feb 20, 2027
Drug: AND017 capsules; ESA · For: Anemia Due to Chronic Kidney Disease
Sites: Shanghai, China
- A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06230224 · 216 participants · Start Feb 15, 2024 · Primary completion May 29, 2028
Drug: Odronextamab; Ifosfamide and 7 more · For: B-Cell Non-Hodgkin Lymphoma (B-NHL)
Sites: Ciudad Autonoma de Buenos Aires, Argentina; La Plata, Argentina; San Juan Bautista, Argentina · 81 sites in all
- A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular LymphomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06097364 · 733 participants (planned) · Start Nov 14, 2023 · Primary completion Jul 29, 2029
Drug: Odronextamab; Rituximab and 4 more · For: Follicular Lymphoma (FL)
Sites: Plantation, Florida; Noblesville, Indiana; Wichita, Kansas · 145 sites in all
- A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05057494 · 607 participants · Start Sep 12, 2022 · Primary completion Jul 15, 2027
Drug: Acalabrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sites: Tucson, Arizona; La Jolla, California; Longmont, Colorado · 37 sites in all
- Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04246047 · 494 participants · Start May 7, 2020 · Primary completion Oct 2, 2023
Drug: Belantamab mafodotin; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Yuma, Arizona; Mission, Kansas; Denver, North Carolina · 143 sites in all
- Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05653349 · 226 participants · Start Feb 3, 2023 · Primary completion Oct 29, 2026
Drug: Ianalumab; Placebo and 1 more · For: Primary Immune Thrombocytopenia (ITP)
Sites: Yuma, Arizona; Clovis, California; Fountain Valley, California · 99 sites in all
- Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT07216079 · 3 participants · Start Oct 15, 2025 · Primary completion Nov 25, 2026
Drug: rilzabrutinib · For: Immune Thrombocytopenia
Sites: Tsuchiura, Japan; Kanazawa, Japan; Iruma-gun, Japan
- A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in ChinaPivotal-lookingActive, not recruiting
GenmabIndustry
NCT07226752 · 72 participants · Start Oct 8, 2022 · Primary completion Oct 13, 2025
Drug: Epcoritamab; Investigator's Choice Chemotherapy · For: Diffuse Large B-Cell Lymphoma
Sites: Baoding, China; Beijing, China; Changchun, China · 23 sites in all
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement InhibitionPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04654468 · 51 participants · Start Mar 17, 2021 · Primary completion Feb 10, 2022
Drug: Crovalimab · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Wuhan, China; Chengdu, China; Guangzhou, China · 5 sites in all
- A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed SteroidsPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05653219 · 152 participants · Start Feb 2, 2023 · Primary completion Jun 19, 2025
Drug: Ianalumab; Eltrombopag and 1 more · For: Primary Immune Thrombocytopenia
Sites: Yuma, Arizona; Aurora, Colorado; Evanston, Illinois · 74 sites in all
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Pivotal-lookingActive, not recruiting
Nanjing IASO Biotechnology Co., Ltd.Industry
NCT06464991 · 260 participants (planned) · Start Mar 27, 2024 · Primary completion Aug 2027
Drug: Equecabtagene Autoleucel Injection; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Beijing, China; Changchun, China; Chengdu, China · 41 sites in all
- A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia BPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT03861273 · 51 participants · Start Jul 29, 2019 · Primary completion Nov 16, 2022
Drug: PF-06838435/ fidanacogene elaparvovec · For: Hemophilia B
Sites: San Francisco, California; Aurora, Colorado; Indianapolis, Indiana · 65 sites in all
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05572515 · 614 participants · Start Mar 29, 2023 · Primary completion Oct 13, 2025
Drug: Teclistamab; Pomalidomide and 3 more · For: Multiple Myeloma
Sites: Anchorage, Alaska; Gilbert, Arizona; Berkeley, California · 211 sites in all
- A Study of DaratumumabPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05438043 · 214 participants · Start Dec 15, 2022 · Primary completion Jan 31, 2029
Drug: Daratumumab; Carfilzomib and 3 more · For: Multiple Myeloma
Sites: Miami, Florida; Atlanta, Georgia; Ann Arbor, Michigan · 92 sites in all
- A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05171647 · 208 participants · Start Apr 25, 2022 · Primary completion Feb 17, 2025
Drug: Mosunetuzumab; Polatuzumab vedotin and 4 more · For: Non-Hodgkin Lymphoma
Sites: Duarte, California; Chesterfield, Missouri; Austin, Texas · 50 sites in all
- A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Pivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03462719 · 211 participants · Start Apr 17, 2018 · Primary completion Feb 26, 2021
Drug: Ibrutinib; Venetoclax and 3 more · For: Leukemia, Lymphocytic, Chronic, B-Cell
Sites: Louisville, Kentucky; Hackensack, New Jersey; Charlotte, North Carolina · 88 sites in all
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05083169 · 587 participants · Start Oct 14, 2021 · Primary completion Aug 1, 2025
Drug: Daratumumab; Pomalidomide and 3 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Duarte, California; Stanford, California · 176 sites in all
- A Long-term Extension Study of PCI-32765 (Ibrutinib)Pivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01804686 · 539 participants · Start Sep 9, 2013 · Primary completion Dec 31, 2026
Drug: Ibrutinib · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma and 4 more
Sites: Duarte, California; La Jolla, California; Los Angeles, California · 156 sites in all
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04181827 · 419 participants · Start Jun 12, 2020 · Primary completion May 1, 2024
Drug: Cilta-cel; Pomalidomide and 3 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; Stanford, California · 88 sites in all
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05455320 · 864 participants · Start Oct 13, 2022 · Primary completion Jul 30, 2027
Drug: Talquetamab; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Tucson, Arizona; Little Rock, Arkansas; Norwalk, Connecticut · 216 sites in all
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomidePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06208150 · 838 participants · Start Jan 22, 2024 · Primary completion Apr 1, 2026
Drug: Talquetamab; Pomalidomide and 4 more · For: Multiple Myeloma
Sites: Clovis, California; Santa Monica, California; New Haven, Connecticut · 242 sites in all
- A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)Pivotal-lookingActive, not recruiting
GenmabIndustry
NCT04628494 · 483 participants · Start Jan 13, 2021 · Primary completion Oct 13, 2025
Drug: Epcoritamab; Investigator's Choice Chemotherapy · For: Diffuse Large B-cell Lymphoma
Sites: Indianapolis, Indiana; Lexington, Kentucky; Jackson, Michigan · 186 sites in all
- A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial TherapyPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04923893 · 743 participants · Start Aug 19, 2021 · Primary completion Feb 14, 2029
Drug: Bortezomib; Dexamethasone and 4 more · For: Multiple Myeloma
Sites: San Francisco, California; New Haven, Connecticut; Miami, Florida · 136 sites in all
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04861259 · 83 participants · Start Oct 22, 2021 · Primary completion Oct 9, 2025
Drug: Crovalimab · For: Atypical Hemolytic Uremic Syndrome
Sites: San Francisco, California; Aurora, Colorado; Atlanta, Georgia · 41 sites in all
- A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodPivotal-lookingActive, not recruiting
Agios Pharmaceuticals, Inc.Industry
NCT05144256 · 49 participants · Start Jun 8, 2022 · Primary completion May 3, 2024
Drug: Mitapivat; Mitapivat-matching placebo · For: Pediatric Pyruvate Kinase Deficiency; Pediatric Hemolytic Anemia
Sites: Phoenix, Arizona; Palo Alto, California; Atlanta, Georgia · 22 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.